Abstract

Newly diagnosed hypertension that develops during pregnancy after 20 weeks of gestation and goes away after birth is referred to as pregnancy-induced hypertension. Intrauterine growth restriction (IUGR) and foetal discomfort brought on by PIH have the potential to cause foetal death. A significant health problem that must be addressed, particularly in developing nations, is PIH, which is recognised as a global leading cause of maternal and perinatal morbidity and mortality. Prevalence of hypertensive disorders of pregnancy was recorded in 7.8% of cases in India, whereas concomitant preeclampsia was found in 5.4% of the study population. The two most dangerous side effects are eclampsia and HELLP syndrome (hemolysis, high liver enzymes, and low platelet count). Pre-eclampsia and hypertensive disorders of pregnancy are both frequently associated with hypercoagulability. Thrombocytopenia is the most well-known haematological aberration among all the haematological abnormalities that take place in PIH, and its severity rises as the disease becomes more severe.